Nuvalent Stock Price, News & Analysis (NASDAQ:NUVL) $62.00 -2.02 (-3.16%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$61.02▼$63.7650-Day Range$42.08▼$64.5252-Week Range$23.09▼$65.57Volume439,716 shsAverage Volume431,884 shsMarket Capitalization$3.54 billionP/E RatioN/ADividend YieldN/APrice Target$60.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Nuvalent MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.63 Rating ScoreUpside/Downside1.8% Downside$60.86 Price TargetShort InterestBearish21.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$5.61 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.14) to ($3.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.22 out of 5 starsMedical Sector937th out of 949 stocksPharmaceutical Preparations Industry430th out of 434 stocks 1.3 Analyst's Opinion Consensus RatingNuvalent has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $60.86, Nuvalent has a forecasted downside of 1.8% from its current price of $62.00.Amount of Analyst CoverageNuvalent has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted21.02% of the float of Nuvalent has been sold short.Short Interest Ratio / Days to CoverNuvalent has a short interest ratio ("days to cover") of 9.4.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldNuvalent does not currently pay a dividend.Dividend GrowthNuvalent does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NUVL. Previous Next 2.7 News and Social Media Coverage News SentimentNuvalent has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nuvalent this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for NUVL on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nuvalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,611,820.00 in company stock.Percentage Held by Insiders14.77% of the stock of Nuvalent is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.26% of the stock of Nuvalent is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nuvalent are expected to decrease in the coming year, from ($2.14) to ($3.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvalent is -30.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvalent is -30.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvalent has a P/B Ratio of 6.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nuvalent Stock (NASDAQ:NUVL)Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Read More NUVL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NUVL Stock News HeadlinesNovember 17, 2023 | markets.businessinsider.comHold Rating on Nuvalent Continues: Evaluating the Potential of NVL-655 and Anticipated Market ShiftsNovember 14, 2023 | finance.yahoo.comNuvalent Inc (NUVL) Reports Q3 2023 Financial Results and Pipeline ProgressNovember 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 14, 2023 | finanznachrichten.deNuvalent, Inc.: Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial ResultsNovember 14, 2023 | markets.businessinsider.comNuvalent Q3 Loss WidensNovember 14, 2023 | finance.yahoo.comNuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial ResultsNovember 11, 2023 | thestreet.comNuvalent Inc.November 2, 2023 | msn.comNuvalent Inc - (NUVL) Price Target Increased by 40.55% to 76.94November 29, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 1, 2023 | morningstar.comNuvalent Inc Class A NUVLNovember 1, 2023 | finance.yahoo.comNuvalent to Participate in the BMO Virtual BioPharma Spotlight Series: Oncology DayOctober 27, 2023 | msn.comNuvalent director sells $4.65M in common stockOctober 19, 2023 | markets.businessinsider.comNuvalent (NUVL) Gets a Buy from Stifel NicolausOctober 17, 2023 | msn.comWhy Nuvalent Stock Tanked on TuesdayOctober 17, 2023 | nasdaq.comNuvalent Prices Public Offering Of About 5.36 Mln Shares At $56/shrOctober 17, 2023 | msn.comNuvalent prices $300 million stock offeringOctober 16, 2023 | bizjournals.comNuvalent offers $300M in stock after a second cancer drug shows promiseOctober 16, 2023 | markets.businessinsider.comPromising Performance of Nuvalent’s NVL-655 and Its Potential Impact on ALK+ NSCLC Treatment: A Buy RecommendationOctober 13, 2023 | finance.yahoo.comNuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLCOctober 7, 2023 | finance.yahoo.comInsider Sell: Chief Medical Officer Christopher Turner Sells 7,995 Shares of Nuvalent Inc (NUVL)October 6, 2023 | msn.comWhy Nuvalent Stock Skyrocketed 35% This WeekOctober 5, 2023 | msn.comBMO Capital Maintains Nuvalent Inc - (NUVL) Outperform RecommendationOctober 5, 2023 | msn.comJP Morgan Maintains Nuvalent Inc - (NUVL) Overweight RecommendationOctober 5, 2023 | markets.businessinsider.comWhere Nuvalent Stands With AnalystsOctober 5, 2023 | finance.yahoo.comNuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study DataOctober 5, 2023 | seekingalpha.comNuvalent Stock Gains On Lung Cancer Data, But I'd Only Buy On DipOctober 5, 2023 | markets.businessinsider.comPromising Future for Nuvalent: Novel ALK-Selective Inhibitor NVL-655 Bolsters Buy Rating and Increases Target PriceSee More Headlines Receive NUVL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today11/29/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NUVL CUSIPN/A CIK1861560 Webwww.nuvalent.com Phone857-357-7000FaxN/AEmployees89Year FoundedN/APrice Target and Rating Average Stock Price Target$60.86 High Stock Price Target$79.00 Low Stock Price Target$42.00 Potential Upside/Downside-1.8%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,850,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-26.46% Return on Assets-25.20% Debt Debt-to-Equity RatioN/A Current Ratio14.42 Quick Ratio14.42 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.94 per share Price / Book8.93Miscellaneous Outstanding Shares57,030,000Free Float48,602,000Market Cap$3.54 billion OptionableNot Optionable Beta1.32 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. James R. Porter Ph.D. (Age 47)CEO, President & Director Comp: $998.02kProf. Matthew D. Shair Ph.D. (Age 54)Founder, Head of Scientific Advisory Board & Director Comp: $235kMs. Alex Balcom CPA (Age 38)M.B.A., CFO & Treasurer Comp: $654.22kDr. Christopher D. Turner M.D. (Age 54)Chief Medical Officer Comp: $714.26kDr. Benjamin LaneSenior Vice President of Technical OperationsMs. Deborah Ann Miller J.D. (Age 47)Ph.D., Chief Legal Officer & Secretary Comp: $595.96kMr. Matthew MetivierVice President of Human ResourcesMs. Darlene Noci (Age 46)Chief Development Officer Mr. Henry Pelish Ph.D.Senior Vice President of Drug DiscoveryMr. John Soglia Ph.D.Senior Vice President of Translational DevelopmentMore ExecutivesKey CompetitorsEvotecNASDAQ:EVOACADIA PharmaceuticalsNASDAQ:ACADInsmedNASDAQ:INSMHUTCHMEDNASDAQ:HCMMadrigal PharmaceuticalsNASDAQ:MDGLView All CompetitorsInsiders & InstitutionsDeutsche Bank AGBought 2,249 shares on 11/24/2023Ownership: 0.025%Walleye Capital LLCBought 33,979 shares on 11/21/2023Ownership: 0.060%Walleye Trading LLCBought 6,963 shares on 11/21/2023Ownership: 0.012%Tudor Investment Corp Et AlSold 6,172 shares on 11/16/2023Ownership: 0.034%Legal & General Group PlcSold 181 shares on 11/15/2023Ownership: 0.039%View All Insider TransactionsView All Institutional Transactions NUVL Stock Analysis - Frequently Asked Questions Should I buy or sell Nuvalent stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nuvalent in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NUVL shares. View NUVL analyst ratings or view top-rated stocks. What is Nuvalent's stock price target for 2024? 8 brokers have issued 12 month target prices for Nuvalent's stock. Their NUVL share price targets range from $42.00 to $79.00. On average, they predict the company's stock price to reach $60.86 in the next year. This suggests that the stock has a possible downside of 1.8%. View analysts price targets for NUVL or view top-rated stocks among Wall Street analysts. How have NUVL shares performed in 2023? Nuvalent's stock was trading at $29.78 at the beginning of the year. Since then, NUVL stock has increased by 108.2% and is now trading at $62.00. View the best growth stocks for 2023 here. When is Nuvalent's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our NUVL earnings forecast. How were Nuvalent's earnings last quarter? Nuvalent, Inc. (NASDAQ:NUVL) released its earnings results on Tuesday, November, 14th. The company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.01. What ETFs hold Nuvalent's stock? ETFs with the largest weight of Nuvalent (NASDAQ:NUVL) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco DWA SmallCap Momentum ETF (DWAS). When did Nuvalent IPO? (NUVL) raised $151 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. Who are Nuvalent's major shareholders? Nuvalent's stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (13.36%), Northern Trust Corp (0.43%), Ameriprise Financial Inc. (0.37%), Victory Capital Management Inc. (0.37%), Invesco Ltd. (0.37%) and Charles Schwab Investment Management Inc. (0.35%). Insiders that own company stock include Christopher Durant Turner, Darlene Noci, Deborah Ann Miller and Matthew Shair. View institutional ownership trends. How do I buy shares of Nuvalent? Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:NUVL) was last updated on 11/29/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.